血清CA19-9的酶免测定及临床应用

Determination of Serum CA19-9 by Enzyme Immunoassay and Its Clinical Application

本文用生物素—链霉亲和素酶联免疫吸附试验（BSA）对203例血清CA19－9水平进行定量测定。结果显示，在32例胰腺癌组为826±411U／ml，40例肝癌组为107±46．5U／ml，与76例正常人对照组21．2±9．24U／ml比较均有明显差异（P＜0．05），以胰腺癌组升高最显著。在39例胃癌组为25．4±11．0U／ml，与正常对照组比较均无明显差异（P＞0．05）。27例胰腺癌病人术前为910±452U／ml，术后为187±89．0U／ml，血清CA19－9水平明显下降（P＜0．05）。血清CA19－9水平分析对胰腺癌的鉴别诊断、疗效观察及预后评估有较高价值。

CA19-9 is a new tumor-associated antigen. Serum CA19-9 levels are frequently elevated in patients with cancers of the pancreas,liver and colorectum. We have measured CA19-9 levels in 203 serum samples, the mean value of serum CA19-9 in 76 normal human beings was 21. 2 U/ml and those in 32pancreatic cancer and 40 liver cancer patients were 826 U/ml and 107 U/ml respectively. Apparently there was marked elevation of CA19-9 in patients with pancreatic cancer. The levels in the patients with gastric cancer (n=39) or chronic pancreatitis (n=16) were not higher than that in normal individuals. In conclusion, determination of serum CA19-9 is especially helpful in the diagnosis of pancreatic cancer. Increased CA19-9 concentration in serum may strongly indicate progression of pancreatic cancer and poor prognosis.